AI biomarkers:From clinical trialsto real-worldimpact, at scale.
Qure.ai is enabling a paradigm shift in life sciences from reactive care to proactive, data-driven patient identification and management. By harnessing AI-powered clinical intelligence, we translate healthcare data into actionable insights that enable earlier intervention, stage shift & faster access to therapies in a coordinated care pathway.
Meet the Qure team at ASCO 2026 Booth
Translating to equitable healthcare.
01
Stage Shift at Scale
AI-derived biomarkers help identify patients at risk of serious disease earlier in their journey, supporting earlier diagnosis and entry into treatment pathways.
02
Clinical Trials powered by Agentic AI
Agentic AI capabilities help identify and surface potential patient cohorts, enabling life sciences teams to explore faster clinical trial recruitment and program readiness.
03
Clinical intelligence unlocked in real time
AI analyzes routine clinical data to reveal how patients are treated in real-world settings, generating insights that support more informed strategies to optimize care and improve treatment pathways.
04
Guideline-Concordant Decisions
With 26 FDA-cleared findings, Qure.ai supports consistent detection and structured insights that help align care pathways with clinical guidelines.
Trusted by healthcare systems, proven by practice.
We are excited to enter into this collaboration with Qure to deliver tools that will streamline imaging-based tumor burden measurements, an important part of both clinical trials and routine care for cancer patients. The autoRECIST program holds the promise of improving these processes and accelerating the delivery of lifesaving treatments to patients. We are very excited to be working with Qure.ai on this important project.
Jon McDunn, PhD
President
Project Data Sphere
“We are thrilled to collaborate with Qure.ai to support surgeons in diagnosing and treating stroke by enabling quicker decision-making, streamlining data sharing between two hospitals, and improving efficiencies so that more stroke patients in India can be treated within the critical time window."
Michael Blackwell
President and Managing Director
Medtronic India
"Our partnership with Qure.ai represents a critical step in our commitment to the EDISON Alliance's 1 Billion Lives Challenge. Lung cancer remains a major global health concern, and it is through applying AI to screen for lung cancer risk in millions of routine X-rays, that it will provide a low-cost, high-impact way of ensuring at-risk patients enter the right diagnostic and care pathway. This milestone exemplifies our A.Catalyst Network approach to expanding access to digital healthcare and driving sustainable change in the communities we serve."
Nipun Jain
Head of International A.Catalyst Network
AstraZeneca
"The partnership between Medtronic and Qure.ai is a significant stride in revolutionizing stroke care in India. Integrating Qure.ai's AI solutions in our hub-and-spoke model is pivotal, with nearly two million people affected by stroke annually. This collaboration enables rapid analysis of CT scans, facilitating timely treatment. It's remarkable how AI transforms stroke management, especially in regions where access to specialized care is challenging."
Prateek Tiwari
Senior Director of Neuroscience and Specialty Therapies
Medtronic
"Qure.ai’s contribution to stroke management in India, through its partnership with Medtronic, aligns perfectly with our mission at the World Stroke Organization. Their AI-enabled solutions are instrumental in addressing the challenges of stroke care, particularly in areas with limited neurologist availability. This collaboration is vital in ensuring timely and accurate diagnosis and treatment of stroke patients, significantly impacting patient outcomes and reducing the burden of stroke in India."
Dr. Jeyaraj Pandian
President-Elect of the World Stroke Organization and Principal (Dean)
CMC Ludhiana
“Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, continues to drive impactful collaborations and integrating our solutions in lung cancer.”
Anuj Virmani
Managing Director, India
Johnson & Johnson MedTech
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes. Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Ti Hwei How
Vice President, International Oncology
AstraZeneca
"This collaboration between AstraZeneca and Qure.ai exemplifies the EDISON Alliance's vision of leveraging digital innovation to address critical healthcare challenges"
Cindy Hoots
Chief Digital Officer and Chief Information Officer
AstraZeneca
“We are pleased to begin exploring the potential of Qure.ai’s AI-driven imaging solution through the APAC Startup Creasphere innovation program. This pilot-project focuses on co-creating the most effective strategy to support clinicians and improve patient outcomes in APAC, through early detection, enabled by AI”
Alfred Chng
Innovation Manager, APAC Strategy & Innovation
Roche
“Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai’s medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer, TB or Stroke giving the best chance of survival outcomes and improving quality of life for patients.”
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
We are excited to enter into this collaboration with Qure to deliver tools that will streamline imaging-based tumor burden measurements, an important part of both clinical trials and routine care for cancer patients. The autoRECIST program holds the promise of improving these processes and accelerating the delivery of lifesaving treatments to patients. We are very excited to be working with Qure.ai on this important project.
Jon McDunn, PhD
President
Project Data Sphere
“We are thrilled to collaborate with Qure.ai to support surgeons in diagnosing and treating stroke by enabling quicker decision-making, streamlining data sharing between two hospitals, and improving efficiencies so that more stroke patients in India can be treated within the critical time window."
Michael Blackwell
President and Managing Director
Medtronic India
"Our partnership with Qure.ai represents a critical step in our commitment to the EDISON Alliance's 1 Billion Lives Challenge. Lung cancer remains a major global health concern, and it is through applying AI to screen for lung cancer risk in millions of routine X-rays, that it will provide a low-cost, high-impact way of ensuring at-risk patients enter the right diagnostic and care pathway. This milestone exemplifies our A.Catalyst Network approach to expanding access to digital healthcare and driving sustainable change in the communities we serve."
Nipun Jain
Head of International A.Catalyst Network
AstraZeneca
"The partnership between Medtronic and Qure.ai is a significant stride in revolutionizing stroke care in India. Integrating Qure.ai's AI solutions in our hub-and-spoke model is pivotal, with nearly two million people affected by stroke annually. This collaboration enables rapid analysis of CT scans, facilitating timely treatment. It's remarkable how AI transforms stroke management, especially in regions where access to specialized care is challenging."
Prateek Tiwari
Senior Director of Neuroscience and Specialty Therapies
Medtronic
"Qure.ai’s contribution to stroke management in India, through its partnership with Medtronic, aligns perfectly with our mission at the World Stroke Organization. Their AI-enabled solutions are instrumental in addressing the challenges of stroke care, particularly in areas with limited neurologist availability. This collaboration is vital in ensuring timely and accurate diagnosis and treatment of stroke patients, significantly impacting patient outcomes and reducing the burden of stroke in India."
Dr. Jeyaraj Pandian
President-Elect of the World Stroke Organization and Principal (Dean)
CMC Ludhiana
“Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, continues to drive impactful collaborations and integrating our solutions in lung cancer.”
Anuj Virmani
Managing Director, India
Johnson & Johnson MedTech
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes. Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Ti Hwei How
Vice President, International Oncology
AstraZeneca
"This collaboration between AstraZeneca and Qure.ai exemplifies the EDISON Alliance's vision of leveraging digital innovation to address critical healthcare challenges"
Cindy Hoots
Chief Digital Officer and Chief Information Officer
AstraZeneca
“We are pleased to begin exploring the potential of Qure.ai’s AI-driven imaging solution through the APAC Startup Creasphere innovation program. This pilot-project focuses on co-creating the most effective strategy to support clinicians and improve patient outcomes in APAC, through early detection, enabled by AI”
Alfred Chng
Innovation Manager, APAC Strategy & Innovation
Roche
“Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai’s medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer, TB or Stroke giving the best chance of survival outcomes and improving quality of life for patients.”
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
We are excited to enter into this collaboration with Qure to deliver tools that will streamline imaging-based tumor burden measurements, an important part of both clinical trials and routine care for cancer patients. The autoRECIST program holds the promise of improving these processes and accelerating the delivery of lifesaving treatments to patients. We are very excited to be working with Qure.ai on this important project.
Jon McDunn, PhD
President
Project Data Sphere
“We are thrilled to collaborate with Qure.ai to support surgeons in diagnosing and treating stroke by enabling quicker decision-making, streamlining data sharing between two hospitals, and improving efficiencies so that more stroke patients in India can be treated within the critical time window."
Michael Blackwell
President and Managing Director
Medtronic India
"Our partnership with Qure.ai represents a critical step in our commitment to the EDISON Alliance's 1 Billion Lives Challenge. Lung cancer remains a major global health concern, and it is through applying AI to screen for lung cancer risk in millions of routine X-rays, that it will provide a low-cost, high-impact way of ensuring at-risk patients enter the right diagnostic and care pathway. This milestone exemplifies our A.Catalyst Network approach to expanding access to digital healthcare and driving sustainable change in the communities we serve."
Nipun Jain
Head of International A.Catalyst Network
AstraZeneca
"The partnership between Medtronic and Qure.ai is a significant stride in revolutionizing stroke care in India. Integrating Qure.ai's AI solutions in our hub-and-spoke model is pivotal, with nearly two million people affected by stroke annually. This collaboration enables rapid analysis of CT scans, facilitating timely treatment. It's remarkable how AI transforms stroke management, especially in regions where access to specialized care is challenging."
Prateek Tiwari
Senior Director of Neuroscience and Specialty Therapies
Medtronic
"Qure.ai’s contribution to stroke management in India, through its partnership with Medtronic, aligns perfectly with our mission at the World Stroke Organization. Their AI-enabled solutions are instrumental in addressing the challenges of stroke care, particularly in areas with limited neurologist availability. This collaboration is vital in ensuring timely and accurate diagnosis and treatment of stroke patients, significantly impacting patient outcomes and reducing the burden of stroke in India."
Dr. Jeyaraj Pandian
President-Elect of the World Stroke Organization and Principal (Dean)
CMC Ludhiana
“Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, continues to drive impactful collaborations and integrating our solutions in lung cancer.”
Anuj Virmani
Managing Director, India
Johnson & Johnson MedTech
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes. Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Ti Hwei How
Vice President, International Oncology
AstraZeneca
"This collaboration between AstraZeneca and Qure.ai exemplifies the EDISON Alliance's vision of leveraging digital innovation to address critical healthcare challenges"
Cindy Hoots
Chief Digital Officer and Chief Information Officer
AstraZeneca
“We are pleased to begin exploring the potential of Qure.ai’s AI-driven imaging solution through the APAC Startup Creasphere innovation program. This pilot-project focuses on co-creating the most effective strategy to support clinicians and improve patient outcomes in APAC, through early detection, enabled by AI”
Alfred Chng
Innovation Manager, APAC Strategy & Innovation
Roche
“Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai’s medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer, TB or Stroke giving the best chance of survival outcomes and improving quality of life for patients.”
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
We are excited to enter into this collaboration with Qure to deliver tools that will streamline imaging-based tumor burden measurements, an important part of both clinical trials and routine care for cancer patients. The autoRECIST program holds the promise of improving these processes and accelerating the delivery of lifesaving treatments to patients. We are very excited to be working with Qure.ai on this important project.
Jon McDunn, PhD
President
Project Data Sphere
“We are thrilled to collaborate with Qure.ai to support surgeons in diagnosing and treating stroke by enabling quicker decision-making, streamlining data sharing between two hospitals, and improving efficiencies so that more stroke patients in India can be treated within the critical time window."
Michael Blackwell
President and Managing Director
Medtronic India
"Our partnership with Qure.ai represents a critical step in our commitment to the EDISON Alliance's 1 Billion Lives Challenge. Lung cancer remains a major global health concern, and it is through applying AI to screen for lung cancer risk in millions of routine X-rays, that it will provide a low-cost, high-impact way of ensuring at-risk patients enter the right diagnostic and care pathway. This milestone exemplifies our A.Catalyst Network approach to expanding access to digital healthcare and driving sustainable change in the communities we serve."
Nipun Jain
Head of International A.Catalyst Network
AstraZeneca
"The partnership between Medtronic and Qure.ai is a significant stride in revolutionizing stroke care in India. Integrating Qure.ai's AI solutions in our hub-and-spoke model is pivotal, with nearly two million people affected by stroke annually. This collaboration enables rapid analysis of CT scans, facilitating timely treatment. It's remarkable how AI transforms stroke management, especially in regions where access to specialized care is challenging."
Prateek Tiwari
Senior Director of Neuroscience and Specialty Therapies
Medtronic
"Qure.ai’s contribution to stroke management in India, through its partnership with Medtronic, aligns perfectly with our mission at the World Stroke Organization. Their AI-enabled solutions are instrumental in addressing the challenges of stroke care, particularly in areas with limited neurologist availability. This collaboration is vital in ensuring timely and accurate diagnosis and treatment of stroke patients, significantly impacting patient outcomes and reducing the burden of stroke in India."
Dr. Jeyaraj Pandian
President-Elect of the World Stroke Organization and Principal (Dean)
CMC Ludhiana
“Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, continues to drive impactful collaborations and integrating our solutions in lung cancer.”
Anuj Virmani
Managing Director, India
Johnson & Johnson MedTech
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes. Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Ti Hwei How
Vice President, International Oncology
AstraZeneca
"This collaboration between AstraZeneca and Qure.ai exemplifies the EDISON Alliance's vision of leveraging digital innovation to address critical healthcare challenges"
Cindy Hoots
Chief Digital Officer and Chief Information Officer
AstraZeneca
“We are pleased to begin exploring the potential of Qure.ai’s AI-driven imaging solution through the APAC Startup Creasphere innovation program. This pilot-project focuses on co-creating the most effective strategy to support clinicians and improve patient outcomes in APAC, through early detection, enabled by AI”
Alfred Chng
Innovation Manager, APAC Strategy & Innovation
Roche
“Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai’s medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer, TB or Stroke giving the best chance of survival outcomes and improving quality of life for patients.”
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
We are excited to enter into this collaboration with Qure to deliver tools that will streamline imaging-based tumor burden measurements, an important part of both clinical trials and routine care for cancer patients. The autoRECIST program holds the promise of improving these processes and accelerating the delivery of lifesaving treatments to patients. We are very excited to be working with Qure.ai on this important project.
Jon McDunn, PhD
President
Project Data Sphere
“We are thrilled to collaborate with Qure.ai to support surgeons in diagnosing and treating stroke by enabling quicker decision-making, streamlining data sharing between two hospitals, and improving efficiencies so that more stroke patients in India can be treated within the critical time window."
Michael Blackwell
President and Managing Director
Medtronic India
"Our partnership with Qure.ai represents a critical step in our commitment to the EDISON Alliance's 1 Billion Lives Challenge. Lung cancer remains a major global health concern, and it is through applying AI to screen for lung cancer risk in millions of routine X-rays, that it will provide a low-cost, high-impact way of ensuring at-risk patients enter the right diagnostic and care pathway. This milestone exemplifies our A.Catalyst Network approach to expanding access to digital healthcare and driving sustainable change in the communities we serve."
Nipun Jain
Head of International A.Catalyst Network
AstraZeneca
"The partnership between Medtronic and Qure.ai is a significant stride in revolutionizing stroke care in India. Integrating Qure.ai's AI solutions in our hub-and-spoke model is pivotal, with nearly two million people affected by stroke annually. This collaboration enables rapid analysis of CT scans, facilitating timely treatment. It's remarkable how AI transforms stroke management, especially in regions where access to specialized care is challenging."
Prateek Tiwari
Senior Director of Neuroscience and Specialty Therapies
Medtronic
"Qure.ai’s contribution to stroke management in India, through its partnership with Medtronic, aligns perfectly with our mission at the World Stroke Organization. Their AI-enabled solutions are instrumental in addressing the challenges of stroke care, particularly in areas with limited neurologist availability. This collaboration is vital in ensuring timely and accurate diagnosis and treatment of stroke patients, significantly impacting patient outcomes and reducing the burden of stroke in India."
Dr. Jeyaraj Pandian
President-Elect of the World Stroke Organization and Principal (Dean)
CMC Ludhiana
“Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, continues to drive impactful collaborations and integrating our solutions in lung cancer.”
Anuj Virmani
Managing Director, India
Johnson & Johnson MedTech
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes. Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Ti Hwei How
Vice President, International Oncology
AstraZeneca
"This collaboration between AstraZeneca and Qure.ai exemplifies the EDISON Alliance's vision of leveraging digital innovation to address critical healthcare challenges"
Cindy Hoots
Chief Digital Officer and Chief Information Officer
AstraZeneca
“We are pleased to begin exploring the potential of Qure.ai’s AI-driven imaging solution through the APAC Startup Creasphere innovation program. This pilot-project focuses on co-creating the most effective strategy to support clinicians and improve patient outcomes in APAC, through early detection, enabled by AI”
Alfred Chng
Innovation Manager, APAC Strategy & Innovation
Roche
“Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai’s medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer, TB or Stroke giving the best chance of survival outcomes and improving quality of life for patients.”
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
We are excited to enter into this collaboration with Qure to deliver tools that will streamline imaging-based tumor burden measurements, an important part of both clinical trials and routine care for cancer patients. The autoRECIST program holds the promise of improving these processes and accelerating the delivery of lifesaving treatments to patients. We are very excited to be working with Qure.ai on this important project.
Jon McDunn, PhD
President
Project Data Sphere
“We are thrilled to collaborate with Qure.ai to support surgeons in diagnosing and treating stroke by enabling quicker decision-making, streamlining data sharing between two hospitals, and improving efficiencies so that more stroke patients in India can be treated within the critical time window."
Michael Blackwell
President and Managing Director
Medtronic India
"Our partnership with Qure.ai represents a critical step in our commitment to the EDISON Alliance's 1 Billion Lives Challenge. Lung cancer remains a major global health concern, and it is through applying AI to screen for lung cancer risk in millions of routine X-rays, that it will provide a low-cost, high-impact way of ensuring at-risk patients enter the right diagnostic and care pathway. This milestone exemplifies our A.Catalyst Network approach to expanding access to digital healthcare and driving sustainable change in the communities we serve."
Nipun Jain
Head of International A.Catalyst Network
AstraZeneca
"The partnership between Medtronic and Qure.ai is a significant stride in revolutionizing stroke care in India. Integrating Qure.ai's AI solutions in our hub-and-spoke model is pivotal, with nearly two million people affected by stroke annually. This collaboration enables rapid analysis of CT scans, facilitating timely treatment. It's remarkable how AI transforms stroke management, especially in regions where access to specialized care is challenging."
Prateek Tiwari
Senior Director of Neuroscience and Specialty Therapies
Medtronic
"Qure.ai’s contribution to stroke management in India, through its partnership with Medtronic, aligns perfectly with our mission at the World Stroke Organization. Their AI-enabled solutions are instrumental in addressing the challenges of stroke care, particularly in areas with limited neurologist availability. This collaboration is vital in ensuring timely and accurate diagnosis and treatment of stroke patients, significantly impacting patient outcomes and reducing the burden of stroke in India."
Dr. Jeyaraj Pandian
President-Elect of the World Stroke Organization and Principal (Dean)
CMC Ludhiana
“Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, continues to drive impactful collaborations and integrating our solutions in lung cancer.”
Anuj Virmani
Managing Director, India
Johnson & Johnson MedTech
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes. Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Ti Hwei How
Vice President, International Oncology
AstraZeneca
"This collaboration between AstraZeneca and Qure.ai exemplifies the EDISON Alliance's vision of leveraging digital innovation to address critical healthcare challenges"
Cindy Hoots
Chief Digital Officer and Chief Information Officer
AstraZeneca
“We are pleased to begin exploring the potential of Qure.ai’s AI-driven imaging solution through the APAC Startup Creasphere innovation program. This pilot-project focuses on co-creating the most effective strategy to support clinicians and improve patient outcomes in APAC, through early detection, enabled by AI”
Alfred Chng
Innovation Manager, APAC Strategy & Innovation
Roche
“Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai’s medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer, TB or Stroke giving the best chance of survival outcomes and improving quality of life for patients.”
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
We are excited to enter into this collaboration with Qure to deliver tools that will streamline imaging-based tumor burden measurements, an important part of both clinical trials and routine care for cancer patients. The autoRECIST program holds the promise of improving these processes and accelerating the delivery of lifesaving treatments to patients. We are very excited to be working with Qure.ai on this important project.
Jon McDunn, PhD
President
Project Data Sphere
“We are thrilled to collaborate with Qure.ai to support surgeons in diagnosing and treating stroke by enabling quicker decision-making, streamlining data sharing between two hospitals, and improving efficiencies so that more stroke patients in India can be treated within the critical time window."
Michael Blackwell
President and Managing Director
Medtronic India
"Our partnership with Qure.ai represents a critical step in our commitment to the EDISON Alliance's 1 Billion Lives Challenge. Lung cancer remains a major global health concern, and it is through applying AI to screen for lung cancer risk in millions of routine X-rays, that it will provide a low-cost, high-impact way of ensuring at-risk patients enter the right diagnostic and care pathway. This milestone exemplifies our A.Catalyst Network approach to expanding access to digital healthcare and driving sustainable change in the communities we serve."
Nipun Jain
Head of International A.Catalyst Network
AstraZeneca
"The partnership between Medtronic and Qure.ai is a significant stride in revolutionizing stroke care in India. Integrating Qure.ai's AI solutions in our hub-and-spoke model is pivotal, with nearly two million people affected by stroke annually. This collaboration enables rapid analysis of CT scans, facilitating timely treatment. It's remarkable how AI transforms stroke management, especially in regions where access to specialized care is challenging."
Prateek Tiwari
Senior Director of Neuroscience and Specialty Therapies
Medtronic
"Qure.ai’s contribution to stroke management in India, through its partnership with Medtronic, aligns perfectly with our mission at the World Stroke Organization. Their AI-enabled solutions are instrumental in addressing the challenges of stroke care, particularly in areas with limited neurologist availability. This collaboration is vital in ensuring timely and accurate diagnosis and treatment of stroke patients, significantly impacting patient outcomes and reducing the burden of stroke in India."
Dr. Jeyaraj Pandian
President-Elect of the World Stroke Organization and Principal (Dean)
CMC Ludhiana
“Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions, continues to drive impactful collaborations and integrating our solutions in lung cancer.”
Anuj Virmani
Managing Director, India
Johnson & Johnson MedTech
"Reaching this milestone underscores our commitment to driving progress towards early detection, the first step on the path to ultimately improved patient outcomes. Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference.”
Ti Hwei How
Vice President, International Oncology
AstraZeneca
"This collaboration between AstraZeneca and Qure.ai exemplifies the EDISON Alliance's vision of leveraging digital innovation to address critical healthcare challenges"
Cindy Hoots
Chief Digital Officer and Chief Information Officer
AstraZeneca
“We are pleased to begin exploring the potential of Qure.ai’s AI-driven imaging solution through the APAC Startup Creasphere innovation program. This pilot-project focuses on co-creating the most effective strategy to support clinicians and improve patient outcomes in APAC, through early detection, enabled by AI”
Alfred Chng
Innovation Manager, APAC Strategy & Innovation
Roche
“Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai’s medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer, TB or Stroke giving the best chance of survival outcomes and improving quality of life for patients.”
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
At ASCO, we bring the science and practice of translation to improve oncology outcomes worldwide.
